The impact of bias and fraud on research integrity
Unless the overall treatment and services provided to schizophrenia patients in Finland is unique and especially protective—which the authors do not suggest—their claimed findings of lowered mortality rates for antipsychotic drug users are belied by a consistent body of evidence.
So far as I can tell, the panel that I was asked to participate in was the only one that focused on the pharmaceutical industry.
The study, reported in The Journal of the American Medical Association, "found no evidence of an association between the serotonin gene and the risk of depression, no matter what people’s life experience was."
Two important analyses in Open Medicine , a peer-reviewed, independent, open-access journal, focus on methodological flaws in data analysis of randomized drug trials.
AHRP proposes a multi-disciplinary team of independent scientists to review ALL of Dr. Joseph Biederman’s publications and supporting documents, including: research protocols, consent forms, and the original (of course, anonymized) data sets with associated code books for all pediatric studies.
The re-prioritization of rapid approvals occurred at the expense of drug safety standards,
A federal Judge of the Eastern District (Brooklyn) issued a ruling upholding a seal on documents that contain evidence linking Zyprexa, Eli Lilly's antipsychotic drug to diabetes
Today's news reports about an increase suicide rate in 2004 offer an opportunity to witness how the media unwittingly disseminates pharmaceutical industry generated propaganda.
Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.
The authors argue that recommendations for the expanded use of statins to stave off cardiovascular disease are NOT supported by the evidence.
PRESS BRIEFING: Critique of FDA Report: “Clinical review relationship between antidepressant drugs and suicidality in adults, 2006” http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-index.htm
U.S. State Attorneys General should investigate the fraudulent marketing of the atypical neuroleptic drugs-and FDA's role in helping conceal the truth.
